Welcome To Weight Loss Clinics

GLP-1 agonists like semaglutide (marketed as Ozempic or Wegovy) represent a breakthrough in the pharmacological approach to successful weight management.

The typical weight loss program in Mississauga involves a weekly or daily subcutaneous injection, with dosage adjustments over time to reach an effective maintenance dose over several months.

Clinical trials have demonstrated that this class of medications can lead to substantial weight loss, with participants achieving an average reduction of about 15% of body weight.

This level of weight loss not only impacts physical appearance but also significantly improves metabolic health, which can help mitigate complications of obesity like type 2 diabetes. 

Common side effects may include gastrointestinal issues like nausea, vomiting, and diarrhea, which are generally mild to moderate but can lead to discontinuation in some cases.

The prognosis for weight maintenance varies; while on the medication, weight loss can be sustained, but discontinuation may lead to weight regain, suggesting need for maintenance.

Food addiction, like other addictions, involves an harmful but compulsive relationship with certain high-calorie foods, typically those high in sugar, fat, or both.

The cravings for these calorie-dense foods can trigger the brain’s reward system, leading to cravings and loss of control over consumption despite adverse outcomes.

This addiction might stem from genetic predispositions, environmental factors, or psychological conditions like stress or emotional eating.

Over time, the course of food addiction can perpetuate a cycle of binge eating followed by guilt or attempts at restriction, similar to substance abuse cycles.

Complications include not only obesity and related health issues like diabetes and cardiovascular diseases but also significant psychological distress.

The distress can include social isolation, and impaired quality of life, highlighting the need for treatments that address both physical and mental health.

Binge Eating Disorder is characterized by recurrent episodes of eating large quantities of food in a short period, often quickly and to the point of discomfort.

 The overeating episodes are often coupled with a feeling of loss of control during the binge, followed by frequent feelings of disgust, depression, or guilt.

This disorder involves a complex interplay of genetic, psychological, and environmental factors which affect mood and impulse control. 

Diagnosis, according to psychiatric criteria, includes recurring episodes of binge eating at least once a week for three months, often associated with distress regarding episodes.

Treatment can include psychotherapy like cognitive behavioral therapy (CBT) to address underlying emotional issues, and other forms of psychological therapy. 

Lisdexamfetamine (Vyvanse) is the first approved drug specifically for Binge Eating Disorder, functioning as a stimulant that helps regulate eating behaviors.